Author(s):
Sushant M. Ahire, Prerana S. Pawar, Vijayraj N. Sonawane, Shivraj P. Jadhav
Email(s):
sushantahire071@gmail.com
DOI:
10.52711/2231-5713.2026.00013 
Address:
Sushant M. Ahire1*, Prerana S. Pawar2, Vijayraj N. Sonawane3, Shivraj P. Jadhav4
1,3Department of Pharmaceutical Chemistry, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
2,4Department of Pharmaceutics, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2026
ABSTRACT:
The emergence of personalized medicine represents a paradigm shift in modern healthcare, where treatments are increasingly tailored to the unique genetic, environmental, and lifestyle factors of individual patients. Central to this transformation is pharmacogenomics the study of how genetic variations influence drug response. Understanding the genetic determinants of drug metabolism, efficacy, and toxicity enables healthcare providers to optimize therapeutic strategies, minimize adverse drug reactions (ADRs), and enhance overall treatment outcomes. This review presents a comprehensive overview of the critical role of genetic polymorphisms and pharmacogenes in influencing interindividual variability in drug response. It discusses key examples such as CYP450 enzymes, TPMT, HLA alleles, and drug transporters, which have demonstrated significant clinical relevance in guiding drug selection and dosage adjustments. The integration of pharmacogenomic data into routine clinical practice is explored, with a focus on its application in targeted therapies, chronic disease management, and ADR prevention. Furthermore, this paper examines the practical challenges in clinical implementation, including issues related to cost, education, healthcare infrastructure, and population diversity. It also outlines future perspectives, highlighting the potential of emerging technologies such as whole-genome sequencing, artificial intelligence (AI), and point-of-care genetic testing in facilitating broader adoption of pharmacogenomics. As the field evolves, pharmacogenomics is poised to become an essential component of precision medicine offering more predictive, preventive, and personalized healthcare for diverse populations worldwide.
Cite this article:
Sushant M. Ahire, Prerana S. Pawar, Vijayraj N. Sonawane, Shivraj P. Jadhav. Personalized Medicine and Pharmacogenomics: Impact of Genetic variation on Drug Response and Individualized Therapy - A Review. Asian Journal of Pharmacy and Technology. 2026; 16(1):91-8. doi: 10.52711/2231-5713.2026.00013
Cite(Electronic):
Sushant M. Ahire, Prerana S. Pawar, Vijayraj N. Sonawane, Shivraj P. Jadhav. Personalized Medicine and Pharmacogenomics: Impact of Genetic variation on Drug Response and Individualized Therapy - A Review. Asian Journal of Pharmacy and Technology. 2026; 16(1):91-8. doi: 10.52711/2231-5713.2026.00013 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-1-13
REFERENCES:
1. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017; 7(1):3-5.
2. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacol Rev. 2023; 75(4):789-814.
3. Swapnaa B, Santhosh Kumar V. Personalized Medicine - A Novel approach in Cancer Therapy. Research J. Pharm. and Tech. 2017; 10(1): 341-345.
4. Madian AG, Wheeler HE, Jones RB, Dolan ME. Relating human genetic variation to variation in drug responses. Trends Genet. 2012; 28(10):487-95.
5. Armila Sen, Komal Kumar, Shaheen Khan, Priyanka Pathak, Arjun Singh. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024; 14(1):77-4.
6. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005; 54(3):171-96.
7. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med. 2011; 17(5):244-51.
8. Isvoran A, Louet M, Vladoiu DL, Craciun D, Loriot MA, Villoutreix BO, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017; 22(2):366-76.
9. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015; 54:709-35.
10. Sahil Mahajan, Heemani Dave, Santosh Bothe, Debarshikar Mahpatra, Sandeep Sonawane, Sanjay Kshirsagar, Santosh Chhajed. Objective Monitoring of Cardiovascular Biomarkers using Artificial Intelligence (AI). Asian Journal of Pharmaceutical Research. 2022; 12(3):229-4.
11. Katara P, Yadav A. Pharmacogenes (PGx-genes): current understanding and future directions. Gene. 2019; 718:144050.
12. Sangeet Kumar Mall, Priti Dipa, Shambaditya Goswami, Prashant Singh, Ravindra Pal Singh. Pharmacovigilance programme in India (PvPI): History, Current scenario, future aspects and role in COVID 19. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(3):205-9.
13. Yukta Ajaykumar Patel, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar. Asian Journal of Pharmacy and Technology. 2025; 15(1):51-6.
14. Gharge Deepali, Bavaskar Sunil, Todkar Pavan,Dhabale Pandurang. Pharmacogenomics: An Overview. Research J. Pharmacology and Pharmacodynamics. 2009; 1(2): 59-65.
15. Zhou S, Brink. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006; 1(1):119-28.
16. Lin R, Wang X, Zhou W, Fu W, Wang Y, Huang W, et al. Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population. Ann Hum Genet. 2011; 75(2):305-11.
17. Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn. 2001; 3(3):98-104.
18. Roman YM. Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics. Pharmacogenomics. 2025; :1-8.
19. Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Front Pharmacol. 2021; 12:651720.
20. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014; 15:349-70.
21. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019; 38(1):156.
22. Wensing M, Oxman A, Baker R, Godycki-Cwirko M, Flottorp S, Szecsenyi J, et al. Tailored implementation for chronic diseases (TICD): a project protocol. Implement Sci. 2011; 6:1-8.
23. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research J. Pharm. and Tech 2019; 12(8):3989-3992.
24. Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: a genetic approach to drug development and therapy. Pharmaceuticals. 2024; 17(7):940.
25. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract. 2012; 25(4):417-27.
26. Adamu Yau, Nordin Bin Simbak, Mainul Haque. Pharmacogenovigilance: A Potential Tool in Pharmacovigilance. Research J. Pharm. and Tech. 7(12): Dec. 2014; Page 1476-1482.
27. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017; 101(3):341-58.
28. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017; 106(9):2368-79.
29. Wake DT, Smith DM, Kazi S, Dunnenberger HM. Pharmacogenomic clinical decision support: a review, how-to guide, and future vision. Clin Pharmacol Ther. 2022; 112(1):44-57.
30. Rayees N M, Sampath Kumar, Bharath Raj K C, Rajesh K S, Juno J Joel, Prasanna Shama K, Gururaja M P, Nandakumar U P. A Prospective Observational Study on Adverse Drug Reactions in General Medicine Department of a Tertiary Care Teaching Hospital. Research J. Pharm. and Tech. 2019; 12(5):2289-2298.
31. Omran S, Leong SL, Blebil A, Mohan D, Teoh SL. Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: a systematic review. Res Social Adm Pharm. 2023; 19(11):1399-411.
32. Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019; 9(3):40.
33. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 2013; 13(4):378-88.
34. Rudschies C, Schneider I. Ethical, legal, and social implications (ELSI) of virtual agents and virtual reality in healthcare. Soc Sci Med. 2024; 340:116483.
35. Ji X, Ning B, Liu J, Roberts R, Lesko L, Tong W, et al. Towards population-specific pharmacogenomics in the era of next-generation sequencing. Drug Discov Today. 2021; 26(8):1776-83.
36. Moyer AM, Black JL. Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities. Ann Lab Med. 2025; 45(3):247-58.
37. Cavallari LH, Hicks JK, Patel JN, Elchynski AL, Smith DM, Bargal SA, et al. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Pharmacogenet Genomics. 2025; 35(1):1-11.
38. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011; 89(3):464-7.
39. Alshabeeb MA, Alyabsi M, Aziz MA, Abohelaika S. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB. Front Med. 2022; 9:1001876.
40. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023; 24(6):350-62.
41. Ishikawa T, Ware J. Future perspectives. Pharmacogenomics of human drug transporters: clinical impacts. 2013; :401-16.
42. Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, et al. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021; 296:113649.
43. Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, et al. Insurance coverage policies for pharmacogenomic and multi-gene testing for cancer. J Pers Med. 2018; 8(2):19.
44. Scott SA. Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther. 2013; 93(1):33-5.
45. Solaiman M, Tisha SJ, Dawood M. Artificial intelligence in the field of pharmacogenomics. Int J Eng Technol Res Manag. 2025; 9(04).
46. Lin E, Lin CH, Lane HY. Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches. Int J Mol Sci. 2020; 21(3):969.
47. Smith DM, Wake DT, Dunnenberger HM. Pharmacogenomic clinical decision support: a scoping review. Clin Pharmacol Ther. 2023; 113(4):803-15.
48. Popejoy AB. Diversity in precision medicine and pharmacogenetics: methodological and conceptual considerations for broadening participation. Pharmacogenomics Pers Med. 2019; :257-71.
49. Zhang H, De T, Zhong Y, Perera MA. The advantages and challenges of diversity in pharmacogenomics: can minority populations bring us closer to implementation? Clin Pharmacol Ther. 2019; 106(2):338-49.
50. Mirsadeghi S, Larijani B. Personalized medicine: pharmacogenomics and drug development. Acta Med Iran. 2017; :150-65.
51. Limaye N. Pharmacogenomics, theranostics and personalized medicine-the complexities of clinical trials: challenges in the developing world. Appl Transl Genom. 2013; 2:17-21.
52. Peterson-Iyer K. Pharmacogenomics, ethics, and public policy. Kennedy Inst Ethics J. 2008; 18(1):35-56.
53. Paul NW, Roses AD. Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. J Mol Med. 2003; 81:135-40.
54. Alanazi DHK, Alanazi AHK, Alanazi SAK, Alanazi BFA, Alfaqeer AA, Aljohani FS, et al. Pharmacogenomics: implications for nursing and pharmacy collaboration in personalized medicine. J Int Crisis Risk Commun Res. 2024; 7(S11).
55. Mukund M. Pache, Rutuja R. Pangavhane, Siddhi V. Nikam, Ramdas B. Rode, Avinash B. Darekar. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025; 15(3):296-4.